Venous Thromboembolism and Mortality Associated With Tranexamic Acid Use During Total Hip and Knee Arthroplasty

Christopher M. Duncan, MD a, Blake P. Gillette, MD b, Adam K. Jacob, MD a, Rafael J. Sierra, MD c, Joaquin Sanchez-Sotelo, MD, PhD d, Hugh M. Smith, MD, PhD a

a Department of Anesthesia, Mayo Clinic College of Medicine, Rochester, Minnesota
b Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota
c Department of Orthopedics, Mayo Clinic College of Medicine, Rochester, Minnesota

ARTICLE INFO

Article history:
Received 5 June 2014
Accepted 27 August 2014
Available online xxxx

Keywords:
tranexamic acid
knee arthroplasty
venothromboembolism
hip arthroplasty
mortality

There is compelling evidence demonstrating a beneficial blood-sparing effect of tranexamic acid (TA) administration in total joint arthroplasty, but unanswered questions remain regarding its potential safety [1–12]. It is well known that synthetic lysine antifibrinolytics such as tranexamic acid prevent clot breakdown by reducing fibrin degradation [13]. While this process reduces blood loss, there is concern that reduction in clot breakdown may increase the risk of postoperative venous thromboembolism (VTE) or death [14,15], especially in procedures associated with high risk for VTE (e.g., THA, TKA) or among “high risk” patients with pre-existing veno-occlusive diseases (e.g., myocardial infarction, stroke, previous VTE). Few studies have tried to directly address the question of TA use in these populations [16].

Total hip and knee arthroplasty have historically been associated with high transfusion rates. Approximately half of patients undergoing lower extremity joint arthroplasty required two units of packed red blood cells to maintain adequate hemoglobin levels [17]. Reported negative effects of blood transfusion include immunosuppression, transfusion reaction, and increased cost [15,18–21]. In addition, blood product transfusion may increase the risk of periprosthetic joint infection [22]. Tranexamic acid has the potential to reduce these transfusion-associated complications as well as decrease the cost of care. TA administration has been shown to reduce the direct hospital cost of joint arthroplasty in healthy patients, and may have an even greater impact in high morbidity patients [23].

While previous studies have reported the frequency of adverse thrombotic events in patients undergoing TKA and THA [24,25], no adequately powered prospective studies have specifically investigated the frequency of VTE in patients receiving TA. Studies examining the hemostatic role of TA have been powered to detect differences in blood loss and blood transfusion. These studies have not been adequately powered to detect frequencies of VTE and all-cause mortality in association with TA administration [1,2,4–6,8,10–12]. Another important limitation of previous investigations of TA in orthopedic surgery is that they have excluded patients with significant pre-existing cardiovascular and thromboembolic disease [23,26,27], leaving open the question of whether TA should be administered to high risk patients. Only a single preliminary study has evaluated the role of TA in high risk patients, showing a slight increase in the odds of postoperative VTE with TA administration [16]. Therefore, the objective of this large, single center, retrospective cohort study was to define the frequency of clinically-significant VTE and all-cause mortality within 30 days of surgery in patients who did and did not receive TA for primary and revision TKA and THA. We hypothesized that TA administration would not increase the frequency of VTE within 30 days of TKA or THA.

Material and Methods

After institutional review board approval, the Orthopedic Department Total Joint Registry (TJR) was searched to identify all patients

http://dx.doi.org/10.1016/j.arth.2014.08.022
0883-5403/© 2014 Elsevier Inc. All rights reserved.
who underwent primary or revision TKA or THA at our institution between January 1, 2005 and January 1, 2010. The TJR is a previously validated and comprehensive repository of data collected for each joint arthroplasty surgery performed at our institution since 1969 [28]. Data included within the TJR have been prospectively defined; and are collected by manual chart review, written patient questionnaire, and follow-up telephone surveys by full-time research assistants unaware of the current study hypothesis. Patients denying access to their medical or administrative records for research purposes were excluded as per Minnesota statute. Patients undergoing simultaneous bilateral procedures were also excluded, as was one patient undergoing both knee and hip arthroplasty due to osteosarcoma. For patients who underwent two joint arthroplasty surgeries within a 30 day period, only the second surgery was included in the analysis.

Patient demographic data (age, gender, weight, and height), date of surgery, surgeon, joint (TKA or THA), side of surgery (right or left), VTE and mortality were collected from the TJR. Height and weight were confirmed by electronic data mining of the medical record. After manual record extraction for missing values, a BMI was calculated for all but four patients who had missing height or weight information. The American Society of Anesthesiology Physical Status (ASA-PS) data were identified by electronic query of the anesthesia record and medical record. The primary outcome variable was presence of clinically significant VTE within 30 days of the date of surgery. Cases of clinically significant VTE were identified from the TJR. The TJR has a dedicated support staff that read all follow-up notes, including phone conversations and radiologic reports each time a patient returns for follow-up. Thromboembolic events are recorded in the TJR if: 1) DVT and/or PE was documented in the medical record by the primary surgeon or 2) if there was radiologic evidence (i.e., ultrasound or computed tomography report) in the medical record documenting the presence of a DVT or PE. Although the collection methods of the TJR have been previously validated for other outcomes [24,29,30], additional validation of the TJR was confirmed through manual chart review of 200 randomly selected patients (100 patients with VTE, 100 patients without VTE). In all 200 patients, the TJR diagnosis of VTE (positive or negative) was confirmed. Patients experiencing multiple events were only counted once.

Following identification of all primary or revision TKA or THA procedures during the 5-year study period, patients who received TA were identified by electronic query of the perioperative datamart. The Perioperative datamart is the access layer of an institutional data warehouse containing detailed information regarding aspects of a patient's surgical encounter (e.g., demographic information, procedural descriptions, locations, start and stop times, detailed physiologic information including vital signs, ventilator data, laboratory information, and fluid, transfusion and medication administration information) [31]. The decision to administer TA was based on surgeon request and judgment of the attending anesthesiologist. Per standard TA protocol, 1000 mg was infused prior to incision and 1000 mg was infused immediately prior to closure. The primary regimen of postoperative anticoagulation was determined using patient medication administration records and/or hospital discharge summaries. Patients were assigned to the following monotherapy anticoagulation groups: aspirin, heparin, low molecular weight heparin (LMWH), or warfarin. If a patient received LMWH as a bridge to warfarin anticoagulation, they were assigned to the warfarin group. A patient who received both warfarin and aspirin following surgery was assigned to the warfarin group. Patients receiving LMWH followed by aspirin were assigned to the LMWH group.

The primary regimen of postoperative anticoagulation was determined by aspirin were assigned to the LMWH group. Similarly, the secondary aim was to calculate the frequency and risk of all-cause mortality in both the TA cohort and non-TA cohort.

Because many patients (>15%) had more than one surgery included in the cohort, the analysis was performed using a generalized linear model framework utilizing generalized estimating equations to properly account for the within-patient correlation. Within this analysis framework, the association of TA use (as well as other risk factors including demographics, patient characteristics, and surgical factors) with the primary outcomes of (1) VTE within 30 days of surgery, and (2) all-cause death within 30 days of surgery were evaluated using logistic regression. Odds ratios are reported with 95% confidence intervals. Because of differences in the populations that received TA and did not receive TA, a propensity score was developed to estimate the probability that a patient received TA conditional on observed patient and surgical data. The propensity score was generated using a logistic regression model, with TA or no TA as the outcome variable, and demographic, clinical, and surgical data as the independent variables. The fitted values from this model represent the propensity that a patient received TA given the observed demographic, clinical, and surgical factors. This propensity score was included as an adjusting covariate in the final multi-variable model for each outcome along with an indicator for TA to minimize the potential bias between the TA and no TA groups. Data were summarized as mean (standard deviation) for continuous variables, and count (percentage) for categorical outcomes, unless otherwise noted. All statistical tests were two-sided and P-values less than 0.05 were considered significant. All analysis was conducted in SAS version 9.2 (SAS Institute, Inc., Cary, NC).

Results

During the study period, a total of 14,100 cases were initially identified. After exclusions, a total of 13,262 elective TKA or THA procedures in 11,175 unique patients were analyzed (Fig. 1). Patient demographic information is summarized in Table 1. At the time of surgery, 71% of subjects were over the age of 60 (median age 67 years). Tranexamic acid was administered intraoperatively in 2785 procedures (21%).

A total of 196 VTE events were identified for an overall frequency of 1.48%. Thirty-seven VTE events (1.3%) were identified among 2785 procedures in which patients received TA, while 159 VTE events (1.5%) were identified among 10,477 procedures in which patients did not.

**Statistical Analysis**

The primary aim of this study was to calculate the frequency and risk of clinically-significant VTE in patients who received TA and in those patients who did not receive TA. Similarly, the secondary aim was to calculate the frequency and risk of all-cause mortality in both the TA cohort and non-TA cohort.

**Fig. 1.** Determination of final study cohort.

<table>
<thead>
<tr>
<th>Starting Cohort:</th>
</tr>
</thead>
<tbody>
<tr>
<td>14,100 cases</td>
</tr>
<tr>
<td>11,480 patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Simultaneous bilateral surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deleted 333 repeated records</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Research refusal</th>
</tr>
</thead>
<tbody>
<tr>
<td>384 records</td>
</tr>
<tr>
<td>304 patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pair of procedures within 30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deleted 119 first surgeries</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Osteosarcoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simultaneous TKA and THA</td>
</tr>
<tr>
<td>Deleted 2 repeated records</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Final Cohort:</th>
</tr>
</thead>
<tbody>
<tr>
<td>13,262 cases</td>
</tr>
<tr>
<td>11,175 patients</td>
</tr>
</tbody>
</table>
receive TA. There was no statistical difference in the adjusted odds of a clinically-significant VTE in patients that did and did not receive TA (OR = 0.98; 95% CI 0.67–1.45; P = 0.939). The odds of VTE within 30 days were significantly greater among simultaneous bilateral surgery (OR = 2.13; 95% CI 1.12–4.06; P = 0.021), primary joint arthroplasty (OR = 1.70; 95% CI 1.12–2.59; P = 0.013), patients undergoing TKA (OR = 1.93; 95% CI 1.43–2.61; P < 0.001), ASA 3–5 (OR = 1.43; 95% CI 1.07–1.90; P = 0.015) and patients receiving warfarin vs. LMWH (OR = 1.61; 95% CI 1.18–2.22; P = 0.001).

Overall, 30 deaths (0.2%) from any cause were identified within 30 days of surgery. One death occurred in a patient who received TA (0.04%), while the remaining 29 deaths were among patients who did not receive TA (0.28%). The cause of death in the patient receiving TA could not be determined and was reported as unknown in both the TJR and the medical record. Based on univariate analysis, patients who did not receive TA had a seven-fold higher risk than patients receiving TA (OR = 7.73; 95% CI 1.05–56.76; P = 0.04). However, after propensity score adjustment, the increased risk of death within 30-days of surgery among patients that did not receive TA was attenuated, and although still high, was no longer statistically significant (adjusted OR = 3.88; 95% CI 0.56–27.1; P = 0.171).

The odds of death within 30 days were significantly greater among males (OR = 2.74; 95% CI 1.26–6.20; P = 0.01), age ≥ 70 (OR = 2.35; 95% CI 1.12–4.93; P = 0.03), patients undergoing THA (OR = 2.70; 95% CI 1.24–5.91; P = 0.01), and ASA 3–5 (OR = 3.56; 95% CI 1.67–7.62; P = 0.001). The most frequent cause of death was a cardiovascular event (37%). Other causes included VTE (10%), respiratory (17%), and other (e.g., sepsis) or unknown (20%).

Univariate analysis was performed comparing VTE frequency with and without TA administration. No statistically significant difference in VTE frequency, TA use and gender, age, BMI, ASA PS, surgery type or the primary anticoagulants was used (Table 2).

Discussion

The primary finding in our large, single institution, retrospective cohort study is that TA administration in TKA and THA did not affect the frequency of VTE within 30 days of surgery. This is consistent with multiple studies currently in the literature, including randomized trials, systematic reviews and meta-analysis [1,2,26,32–34]. Unfortunately, each of the randomized trials was significantly underpowered to detect a difference in the VTE rate. One recent letter to the editor suggested at least 5000 patients per arm would be needed to detect a 1% difference in the VTE rate [35]. Our investigation of 13,000+ patients is the largest series to date investigating the association of TA use and risk for 30-day VTE and mortality. Given the potential time and cost of conducting a large prospective study, a retrospective cohort study like ours may be the most feasible study design to evaluate the safety of TA administration in hypercoagulable TKA and THA patients.

One of the primary concerns regarding TA administration is patient selection, especially in patients with significant vascular occlusive comorbidity. Unlike prior investigations, our study included patients with significant comorbidities including vascular occlusive diseases [2–4,27]. The inclusion of the high morbidity patients improves the generalizability of our findings and is consistent with our preliminary study on high risk patients receiving TA for TKA [16].

The frequency of VTE (1.48%) in the present study is lower than the prior large retrospective studies [24,25] of TKA and THA procedures, but higher than more recent large, retrospective studies [36,37]. White et al [25] reported an overall VTE incidence of 2.8% in over 43,000 patients undergoing primary TKA or THA between 1991 and 1993. During a 10-year cohort study from 1986 to 1995, Mantilla et al [24] reported a clinically-significant VTE frequency of 2.2%. Wu et al [37] reported an overall VTE rate of 0.44% in 114,026 TKA and THA patients from 2002

Please cite this article as: Duncan CM, et al, Venous Thromboembolism and Mortality Associated With Tranexamic Acid Use During Total Hip and Knee Arthroplasty, J Arthroplasty (2014), http://dx.doi.org/10.1016/j.arth.2014.08.022
to 2006. Similarly, Guijarro et al. [36] reported a PE rate of 0.18% and 0.23% and DVT rate of 0.57% and 0.44% for patients undergoing TKA and THA, respectively, during a 2005-2006 study. Compared to older studies, the reduction in VTE frequency in the current investigation is likely due to numerous factors including early ambulation and physical therapy as well as advances in VTE prophylaxis regimens, and possibly TA administration.

There was no association between TA administration and all-cause 30-day mortality. Further, after propensity adjustment, there was a trend toward a protective effect of TA administration (OR = 3.88; \( P = 0.171 \)). In the largest randomized trial of TA administration to date, trauma patients who received the TA experienced a significant reduction in all-cause postoperative mortality [38]. Since the current study was not a randomized trial, a selection bias for withholding TA administration in patients with severe cardiovascular comorbidities remains a possibility. While selection bias may explain the absence of association between TA and all-cause 30-day mortality, an actual protective effect cannot be discounted.

These are important findings given TKA and THA are two of the most commonly performed orthopedic operations and collectively constitute the single largest procedural expenditure in the United States Medicare budget. Moreover, up to half of all these patients may require blood product transfusion during the perioperative period [17,39]. Yet routine blood product administration is increasingly discouraged among surgical patient populations because of the growing list of recognized risks: transfusion reactions, acute lung injury, volume overload, impaired wound healing, and transfusion-associated infections [20]. Among orthopedic patients, blood administration has also been specifically associated with higher rates of postoperative joint infection [22,40,41]. Beyond medical sequelae, blood product administration increases health care expenditures at a rate of $1200/unit PRBC [42,43].

Tranexamic acid has been shown to reduce blood loss and blood transfusion requirements during total joint surgery [1–12]. The reduction in transfusion through the administration of TA has the potential to dramatically reduce the overall cost of TKA and THA. In healthy patients (ASA 1-2), TA was reported to reduce overall direct hospital costs by $879 per patient [23]. Our investigation reports no increased risk of VTE or death with TA administration, including higher risk patients. Widespread use of TA in TKA and THA could result in greater cost savings and may reduce transfusion-related complications in patients with higher morbidity (ASA 3-5).

A significant strength of our investigation was the large volume of TKA and THA operations performed per year. This allowed us to retrospectively include 13,262 cases over a five-year period. The relatively short time period increases the homogeneity in surgical techniques, anesthesia and analgesia, and postoperative recovery pathways. In addition, we were able to access and cross-reference multiple validated institutional databases. This included the ability to combine electronic patient data from our orthopedic department, electronic patient medical record, pharmacy administration record and the electronic anesthesia charting record. An additional strength is the large number of patients treated with a TA dosing strategy reported in previous studies as acceptable. There is no current standard for TA administration in TKA and THA, but multiple dosing strategies have been used successfully [5]. The current recommended dose is 10 to 20 mg/kg. Instead of using weight-based dosing, our practice elected to use two doses of 1000 mg. Our practice has been using the same dosing since 2000. Recently, investigations have failed to demonstrate any significant difference between dosing strategies [44,45].

Inconsistent administration of TA during the study period is the greatest limitation of the present study. During the study period, limited data were available regarding the safety of TA, especially in patients with significant comorbidities. Additionally, during our data collection period, the practice evolved from a few surgeons ordering TA, to all surgeons ordering TA on most patients, resulting in no “standard” for TA administration. Changes in ordering practices by surgeons and selective administration by covering anesthesiologists potentially lead to a selection bias in the administration of TA. However, this limitation is likely minimized in the data by three factors. First, during the majority of the study period only two surgeons ordered TA and it was uniformly ordered regardless of patient comorbidity. Secondly, in the absence of evidence demonstrating increased VTE risks, the majority of anesthesiologists administered the TA regardless of patient comorbidity. Thirdly, a propensity model was developed to correct for TA administration patterns, including differences in anticoagulation regimens. The collection of VTE events was limited to clinically significant VTE. The retrospective nature of our study prevented active VTE screening, resulting in an inability to account for subclinical VTE. In addition, despite extensive validation to try and ensure accurate database information, the retrospective nature of data collection introduces the possibility of missing transient, yet clinically significant events that may not be have been documented. Therefore, even trained abstractors will not be able to identify those events that were 1) clinically present and not documented; or 2) documented >30 days after surgery but occurring during the immediate postoperative period.

**Conclusions**

This study demonstrates that the overall frequency of clinically-significant VTE was lower when TA was administered, and the odds of postoperative VTE were unchanged. Equally important, no statistically significant change was seen in 30-day mortality, although a trend toward reduced mortality with TA administration was observed. Although these results are encouraging, the exact risks of TA administration for patients undergoing THA and TKA remain unclear and our understanding of the safety of antifibrinolytic administration, including TA, remains incomplete. A large prospective, randomized trial is necessary to provide more definitive results to define the risks of TA administration for patients undergoing THA and TKA.

**Acknowledgments**

We would like to acknowledge the contributions of Dirk Larson (Mayo Department of Biostatistics) for his assistance with the statistical analysis and preparation of the statistical methods and results sections of manuscript.

**References**